Journal of Alzheimer's Disease最新文献

{"title":"Toward a person-centered return of research results of dementia risk: A pluralistic, constructive expansion.","authors":"Bilal Irfan, Elijah Wiseman, J Wesley Boyd, Jonathan Reader, Annalise Rahman-Filipiak","doi":"10.1177/13872877251343319","DOIUrl":"https://doi.org/10.1177/13872877251343319","url":null,"abstract":"<p><p>Graham et al.'s article offers a thoughtful account of why disclosing modifiable dementia risk factors to cognitively unimpaired research participants may be ethically defensible. In this Ethics Response, we seek to engage constructively with their arguments, affirming value in a person-centered approach, while also expanding on how cultural, communal, and religious contexts can further illuminate the ethics of returning individual research results. Drawing on emerging ethical issues and examples from diverse settings, this response highlights how stigmatization, religious worldviews, family care traditions, and broader socioeconomic factors may influence the perceived meaning and impact of dementia risk communication.</p>","PeriodicalId":14929,"journal":{"name":"Journal of Alzheimer's Disease","volume":" ","pages":"13872877251343319"},"PeriodicalIF":3.4,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144078112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cognitive training for Alzheimer's disease and other forms of dementia: Insights from a systematic review and Bayesian meta-analysis.","authors":"Francesco Giaquinto, Marika Iaia, Ezia Rizzi, Luigi Macchitella, Daniele Luigi Romano, Giorgia Tosi, Paola Angelelli","doi":"10.1177/13872877251334795","DOIUrl":"https://doi.org/10.1177/13872877251334795","url":null,"abstract":"<p><p>BackgroundThe prevalence of individuals living with mild cognitive impairment (MCI), Alzheimer's disease (AD), and other forms of dementia is globally increasing. Four out of nine international clinical guidelines recommend non-pharmacological cognitive interventions to enhance cognition, independence, and wellbeing. However, the effectiveness of cognitive rehabilitation (CR) and cognitive training (CT) for individuals with MCI and AD and other forms of dementia is still debatable, often due to significant heterogeneity among studies.ObjectiveThis study aims to assess the effectiveness of CT and CR in these populations.MethodsFollowing PRISMA guidelines, we conducted a comprehensive literature search across databases including OVID, MEDLINE, EMBASE, and Scopus, identifying randomized controlled trials and non-randomized pre-post intervention studies. The Bayesian meta-analysis focused on pre-post changes in global cognition, quality of life, everyday functioning, and depression, avoiding comparisons with control groups to reduce heterogeneity (PROSPERO: CRD42022365038).ResultsThe search yielded 6075 results, with 40 studies meeting inclusion criteria, encompassing 50 independent trials. CT and people with AD and other dementias are the best represented intervention and population, respectively. CT was more effective in improving global cognition in individuals with AD and other dementias, and paper-and-pencil and face-to-face formats yielded greater benefits. The analysis showed a significant susceptibility to bias among the studies.ConclusionsLimitations in outcome measure (e.g., MMSE) suggest the need for more sensitive assessments, especially for MCI. Future research should explore broader aspects of wellbeing and investigate the potential of CR. Policymakers are encouraged to consider these findings when designing cognitive interventions for this population.</p>","PeriodicalId":14929,"journal":{"name":"Journal of Alzheimer's Disease","volume":" ","pages":"13872877251334795"},"PeriodicalIF":3.4,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143990840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The complementary role of automated brain volumetry to stratify ADNI participants within the ATN framework.","authors":"Ilaria Ricchi, Alessandra Griffa, Ricardo Corredor-Jerez, Jonas Richiardi, Jean-François Démonet, Gilles Allali, Bénédicte Maréchal, Olivier Rouaud","doi":"10.1177/13872877251339840","DOIUrl":"https://doi.org/10.1177/13872877251339840","url":null,"abstract":"<p><p>BackgroundThe amyloid, tau, neurodegeneration (ATN) framework provides a biological staging model of Alzheimer's disease (AD) using magnetic resonance imaging (MRI), cerebrospinal fluid (CSF), or positron emission tomography (PET) biomarkers. MRI, being non-invasive, accessible, and cost-effective, holds promise as a biomarker.ObjectiveTo evaluate the utility of MRI-based automated brain volumetry in classifying cognitive impairment severity-cognitively unimpaired (CU), mild cognitive impairment (MCI), and dementia-as well as ATN profiles, independently.MethodsWe analyzed 394 subjects from the Alzheimer's Disease Neuroimaging Initiative. First, we assessed how well MRI volumetry stratifies cognitive stages. Next, we tested its ability to distinguish A + T + N+ from A-T-N- individuals while classifying clinical stages. Finally, we evaluated its predictive power for cognitive severity in A + T+ and A-T- subgroups, irrespective of neurodegeneration (N), to examine the added value of volumetry across AT profiles.ResultsMRI volumetry showed comparable performance to established biomarkers in identifying CU, MCI, and dementia, and offered complementary value when combined with phosphorylated tau. Hippocampal and temporal gray matter volumes distinguished A + T + N+ from A-T-N- classes with accuracies of 0.81 and 0.78, respectively. In A + T+ versus A-T- comparisons, the highest classification performance for cognitive severity was observed in the A-T- group.ConclusionsMRI-based brain volumetry can effectively classify cognitive stages and distinguish biological subtypes in AD. It is a promising tool for clinical staging and predicting impairment severity, especially when used alongside phosphorylated tau.</p>","PeriodicalId":14929,"journal":{"name":"Journal of Alzheimer's Disease","volume":" ","pages":"13872877251339840"},"PeriodicalIF":3.4,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144007219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High precision and cost-effective multiplex quantification of amyloid-β40, amyloid-β42, p181Tau, p217Tau, neurofilament light chain, and glial fibrillary acidic protein from plasma and serum.","authors":"Farshad Alishahi, Christopher R Beam, Margaret Gatz, Lon S Schneider, Daniel A Nation, Hussein N Yassine, Hillard Kaplan, Suchita Ganesan, Ioannis Pappas, Deborah Winders Davis, Ebrahim Zandi","doi":"10.1177/13872877251340999","DOIUrl":"https://doi.org/10.1177/13872877251340999","url":null,"abstract":"<p><p>BackgroundCurrent methods to quantify blood biomarkers for Alzheimer's disease (AD) are expensive and are not widely available.ObjectiveTo develop a low-cost, sensitive, and accurate multiplex assay to quantify Aβ₄₀, Aβ₄₂, p181Tau, p217Tau, NfL, and GFAP biomarkers in plasma and serum based on a widely available technology.MethodsWe used commercial antibodies to Aβ₄₀, Aβ₄₂, p181Tau, p217Tau, NfL, and GFAP, and xMAP Luminex technology, and developed the multiplex 5ADCSI to quantify these biomarkers from plasma and serum. The utility of 5ADCSI was tested in matched cerebrospinal fluid (CSF) and plasma or serum of a cohort of cognitively normal (CN: n = 35), with mild cognitive impairment (MCI: n = 17), and with AD (n = 11) individuals.ResultsThe 5ADCSI demonstrated high specificity and sensitivity, with excellent precision. In clinical samples, moderate to strong correlation is observed between CSF and plasma or serum for Aβ_42/40 (<i>r</i> <i>=</i> <i>0.78</i>), p181Tau/Aβ₄₂ (<i>r</i> <i>=</i> <i>0.57</i>), p217Tau/Aβ₄₂ (<i>r</i> <i>=</i> <i>0.72</i>), p181Tau (<i>r</i> <i>=</i> <i>0.59</i>), p217Tau (<i>r</i> <i>=</i> <i>0.75</i>), and GFAP (<i>r</i> <i>=</i> <i>0.59</i>). The AUC of receiver-operator characteristic curve for differentiating CN from AD for plasma/serum and CSF are 0.75, and 0.80 for Aβ_42/40, 0.95, 0.91 for p217Tau, 0.76, 0.81 for p181Tau, and 0.73 and 0.78for GFAP, respectively.ConclusionsThe 5ADCSI assay is highly specific, sensitive, and accurate. The wide availability of the base technology of 5ADCSI is an advantage over other similar methods and would allow cost-effective large-scale studies for validation of blood biomarkers for early diagnosis of AD.</p>","PeriodicalId":14929,"journal":{"name":"Journal of Alzheimer's Disease","volume":" ","pages":"13872877251340999"},"PeriodicalIF":3.4,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143972167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of early-phase ¹⁸F-Florbetaben PET as a surrogate biomarker of neurodegeneration: In-depth comparison with ¹⁸F-FDG PET at group and single patient level.","authors":"Jose Antonio Lojo-Ramírez, Paula Fernández-Rodríguez, Miriam Guerra-Gómez, Alba Marta Marín-Cabañas, Emilio Franco-Macías, Jose Manuel Jiménez-Hoyuela-García, David García-Solís","doi":"10.1177/13872877251340380","DOIUrl":"https://doi.org/10.1177/13872877251340380","url":null,"abstract":"<p><p>BackgroundImaging biomarkers are essential in Alzheimer's disease (AD) diagnosis, particularly since the introduction of the ATN criteria by the NIA-AA. These criteria include amyloid-β plaques (amyloid PET), fibrillar tau (tau PET), and neurodegeneration (FDG PET or MRI). Early-phase amyloid PET imaging has shown a strong correlation with FDG PET at the group level.ObjectiveThis study evaluates the comparability of early-phase FBB PET (eFBB) perfusion imaging and FDG PET metabolic imaging at both group and individual levels.MethodsA retrospective study included 103 patients with mild cognitive impairment (MCI) or mild dementia suspected of AD who underwent FDG PET and dual-phase ¹⁸F-Florbetaben PET (including a 5-min eFBB scan) between 2019 and 2023, along with 33 healthy controls. Imaging analyses included qualitative, semi-quantitative, and voxel-wise techniques to compare eFBB and FDG PET scans.ResultseFBB and FDG PET SUVR values showed a strong correlation across all brain regions (rho = 0.879). Visual assessments of eFBB and FDG PET by two raters achieved intra-observer agreement rates of 87.5% and 86.4%, respectively. Voxel-wise analysis revealed moderate to good overlap, as indicated by Dice-Sørensen coefficients, in the MCI and mild dementia groups. Discriminative performance between eFBB and FDG PET was comparable, with no significant differences as eFBB reliably reflected brain metabolic patterns observed on FDG PET, supporting its diagnostic utility.ConclusionseFBB PET could serve as a surrogate biomarker for FDG PET in the diagnostic evaluation of neurodegenerative dementias. Dual-phase amyloid PET enables simultaneous assessment of neurodegeneration and amyloid burden, offering a streamlined and resource-efficient approach for clinical practice.</p>","PeriodicalId":14929,"journal":{"name":"Journal of Alzheimer's Disease","volume":" ","pages":"13872877251340380"},"PeriodicalIF":3.4,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143966671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"p53 SUMOylation promotes neurogenesis defects in APP/PS1 mice.","authors":"Anqi Yin, Yuran Gui, Lu Wan, Qinfeng Cai, Yong Luo, Jian-Zhi Wang, Rong Liu, Chenjiang Ying, Xiaochuan Wang, Fumin Yang","doi":"10.1177/13872877251340432","DOIUrl":"https://doi.org/10.1177/13872877251340432","url":null,"abstract":"<p><p>Backgroundp53 is a transcriptional factor that regulates numerous cellular processes, the stability and activity of p53 is essential to maintain its function. Post-translational modifications (PTMs), particularly SUMOylation, play a vital role in regulating p53 activity.ObjectiveTo investigate the neurogenesis related genes that downregulated by p53 SUMOylation in APP/PS1 mice, and the protected effect by overexpressing non-SUMOylated p53 (p53 K386R). Furthermore, to provide new clues for the mechanisms of Alzheimer's disease (AD).MethodsCo-immunoprecipitation was used to detect the p53 SUMOylation levels in neuro2a (N2a) cells and APP/PS1 mice overexpressing wild-type p53 (p53 WT) or p53 K386R. In addition, RNA sequencing (RNA-seq) was used to detect the p53 SUMOylation regulated genes. Then we used qPCR, western blot, and immunofluorescence to measure the expression of neuroglobin (ngb) and the effect of neurogenesis defects induced by p53 SUMOylation.ResultsWe verified that overexpression of p53 WT promoted p53 SUMOylation and p53 K386R decreased p53 SUMOylation in N2a cells and APP/PS1 mice. Ngb was related to neurogenesis which dramatically downregulated by p53 SUMOylation. In addition, we found p53 SUMOylation caused neuron reduction and impairment of neurogenesis.ConclusionsOur data support that p53 SUMOylation may lead to neurogenesis defects by downregulating ngb in AD, suggesting that inhibition of p53 SUMOylation may be served as a therapeutic strategy for preventing AD and provide a new target for future researches and interventions.</p>","PeriodicalId":14929,"journal":{"name":"Journal of Alzheimer's Disease","volume":" ","pages":"13872877251340432"},"PeriodicalIF":3.4,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143985000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An inverse association of cerebral amyloid-β deposition and serum docosahexaenoic acid levels in cognitively normal older adults in Japan.","authors":"Akira Sekikawa, Aya Higashiyama, Brian J Lopresti, Masafumi Ihara, Chendi Cui, Jiatong Li, Makoto Watanabe, Mengyi Li, Shatabdi Goon, Howard J Aizenstein, Yuefang Chang, Chikage Kakuta, Zheming Yu, Chester A Mathis, Yoshihiro Kokubo, Sarah Royse, Tetsuya Fukuda, Beth Snitz, Oscar L Lopez, Yoshihiro Miyamoto","doi":"10.1177/13872877251340688","DOIUrl":"https://doi.org/10.1177/13872877251340688","url":null,"abstract":"<p><p>BackgroundAlzheimer's disease (AD) is driven by amyloid-β (Aβ) plaque accumulation, but the mechanisms behind this process remain unclear. Omega-3 fatty acids, particularly docosahexaenoic acid (DHA), may offer protective effects, though their relationship with Aβ accumulation is not fully understood.ObjectiveThis study investigated whether serum DHA and eicosapentaenoic acid (EPA) levels, measured 6-9 years before imaging, were inversely associated with cerebral Aβ deposition in cognitively normal older adults in Japan, a population known for high omega-3 intake. We focused on individuals identified as Aβ-positive based on positron emission tomography (PET) scans, as they are at higher risk for AD progression, to assess DHA's potential in mitigating early amyloid pathology.MethodsAn analytical sample of 97 older adults (75-89 years) from the Suita Study was analyzed. Serum DHA and EPA levels were assessed between 2008 and 2012, and amyloid PET was performed between 2016 and 2019. Multiple regression analyses were conducted, adjusting for age, sex, <i>APOE4</i> status, and cardiometabolic disease.ResultsAmong 97 participants (49% males, 8.2% <i>APOE4</i> carriers), 37.1% (n = 36) had cardiometabolic disease, and 29.8% (n = 29) were Aβ positive. In Aβ-positive individuals, higher serum DHA levels were significantly associated with lower Aβ deposition independent of age, sex and <i>APOE4</i> status (standardized β = -0.423, p = 0.030). This became non-significant after additionally adjusting for cardiometabolic disease (β = -0.382, p = 0.059). No significant association was found between EPA and Aβ deposition.ConclusionsHigher long-term DHA levels may help reduce Aβ accumulation in those at risk for AD, supporting its potential role in early prevention.</p>","PeriodicalId":14929,"journal":{"name":"Journal of Alzheimer's Disease","volume":" ","pages":"13872877251340688"},"PeriodicalIF":3.4,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144019744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Blood biomarkers of amyloid and tau pathologies, brain degeneration, inflammation, and oxidative stress in early- and late-onset Alzheimer's disease.","authors":"Qi Qin, Xinyi Xia, Junda Qu, Zhongtian Guan, Yunsi Yin, Jie Chang, Chaoji Yu, Tongtong Zhang, Yi Tang","doi":"10.1177/13872877251340955","DOIUrl":"https://doi.org/10.1177/13872877251340955","url":null,"abstract":"<p><p>BackgroundNumerous blood biomarkers have emerged as promising biomarkers for Alzheimer's disease (AD) and cognitive decline, but limited knowledge exists concerning the difference of blood biomarkers between early-onset and late-onset cases.ObjectiveInvestigate blood biomarkers associated with amyloid and tau pathologies, brain degeneration, inflammation, and oxidative stress in individuals afflicted with both early-onset and late-onset AD, as well as in age-matched healthy controls.MethodsA total of 125 participants were enrolled. We assessed levels of 18 distinct blood biomarkers and their associations with cerebrospinal fluid biomarkers, neuropsychological test scores, <i>APOE</i> ε4 carrier status, and neuroimaging markers. The diagnostic potential of blood biomarkers was investigated.ResultsIn early-onset AD patients, levels of blood Interleukin (IL)-4, IL-6, and Tumor necrosis factor-alpha (TNF-α) were notably lower comparing to late-onset patients. AD patients exhibited higher blood levels of phosphorylated-tau181 (p-tau181), neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP), as well as lower levels of amyloid-β (Aβ)₄₂ and IL-12p70. Oxidative stress markers, including malondialdehyde, total antioxidant capacity, and superoxide dismutase, exhibited a progressive trend across the continuum of AD. Inflammatory markers demonstrating correlations with neuroimaging markers. Blood levels of Aβ₄₂, p-tau181, NfL, and GFAP associated with neuropsychological scores and effectively discriminated AD, with GFAP exhibiting particular relevance in early-onset cases.ConclusionsInflammatory markers exhibited differences between patients with early- and late-onset AD, associated with alterations in brain structure and function. With the progression of disease continuum, a decrement in antioxidant capacity was observed. Blood Aβ₄₂, p-tau181, NfL, and GFAP showed promise in detecting cognitive decline and AD.</p>","PeriodicalId":14929,"journal":{"name":"Journal of Alzheimer's Disease","volume":" ","pages":"13872877251340955"},"PeriodicalIF":3.4,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144005716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Knowledge, attitude, and practice of neurologists toward primary progressive aphasia in Indonesia.","authors":"Fasihah Irfani Fitri, Boon Lead Tee, Jeanne Gallée, Aldy Safruddin Rambe, Elmeida Effendy, Alfansuri Kadri, Pukovisa Prawiroharjo, Inke Nadia Diniyanti Lubis, Khairul Putra Surbakti, Mustafa Mahmud Amin","doi":"10.1177/13872877251336263","DOIUrl":"https://doi.org/10.1177/13872877251336263","url":null,"abstract":"<p><p>BackgroundPrimary progressive aphasia (PPA) is a neurodegenerative syndrome that impairs language and speech abilities. Limited research exists on PPA in Indonesia, and understanding neurologists' perspectives is crucial for improving early diagnosis and management.ObjectiveThis study aimed to assess Indonesian neurologists' knowledge, attitudes, and practices regarding PPA.MethodsIndonesian neurologists were invited to complete an online questionnaire covering demographics, clinical experiences, understanding of PPA variants and treatments, attitudes toward diagnosis, and current clinical practices.ResultsA total of 192 neurologists completed the survey, predominantly aged 31-40 years (53.15%) with over five years of experience (61.5%). Many reported limited experience with PPA: with 43.8% had never encountered progressive language impairment, and 81.3% had not diagnosed PPA. While knowledge of PPA symptoms and variants was strong, gaps remained, particularly in specific clinical features. Participants recognized the importance of comprehensive assessments and multidisciplinary care, but inconsistencies in evaluations and referrals revealed a gap between knowledge and practice.ConclusionsWhile Indonesian neurologists have a foundational understanding of PPA, there are significant gaps in recognizing variant-specific features, assessment methods, and referral pathways. Addressing these gaps through targeted education and improved diagnostic tools is essential for enhancing patient care.</p>","PeriodicalId":14929,"journal":{"name":"Journal of Alzheimer's Disease","volume":" ","pages":"13872877251336263"},"PeriodicalIF":3.4,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144012550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A sleep-based risk model for predicting dementia: Development and validation in a Korean cohort.","authors":"Hyukjun Lee, Ji Won Han, Seung Wan Suh, Hee Won Yang, Dae Jong Oh, Eunji Lim, Jin Shin, Bong Jo Kim, Dong Woo Lee, Jeong Lan Kim, Jin Hyeong Jhoo, Joon Hyuk Park, Jung Jae Lee, Kyung Phil Kwak, Seok Bum Lee, Seok Woo Moon, Seung-Ho Ryu, Shin Gyeom Kim, Ki Woong Kim","doi":"10.1177/13872877251340094","DOIUrl":"https://doi.org/10.1177/13872877251340094","url":null,"abstract":"<p><p>BackgroundDementia is a major public health challenge, yet existing prediction models often overlook sleep-related symptoms, despite their known links to cognitive decline.ObjectiveTo develop and validate a four-year Dementia Risk Score (DRS) incorporating self-reported sleep-related symptoms with demographic and clinical factors to predict all-cause dementia, including Alzheimer's disease.MethodsData from 3082 Korean adults aged 60-79 years were analyzed. Predictors were selected using LASSO regression and included in a multivariate logistic regression model. A point-based scoring system, the DRS, was constructed from the model coefficients. Internal validation was conducted using bootstrapping and a separate dataset.ResultsThe DRS achieved robust predictive performance, with AUC values of 0.824 in the training set and 0.826 in the validation set. Key predictors included sleep disturbance, use of sleep medications, daytime dysfunction, leg discomfort, and urge to move legs.ConclusionsThe DRS provides a practical, scalable tool for predicting dementia risk, supporting community-based screening and early intervention. External validation is needed to confirm its broader applicability.</p>","PeriodicalId":14929,"journal":{"name":"Journal of Alzheimer's Disease","volume":" ","pages":"13872877251340094"},"PeriodicalIF":3.4,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144010556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}